Krisztina Galgoczy - Supply Chain Specialist - TAPI - Teva Active Pharmaceutical Ingredients | LinkedIn
![Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone - Perlstein - 2022 - Clinical Pharmacology in Drug Development - Wiley Online Library Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone - Perlstein - 2022 - Clinical Pharmacology in Drug Development - Wiley Online Library](https://accp1.onlinelibrary.wiley.com/cms/asset/b6a8db80-4c6e-4e6b-b42c-ed086ce80239/cpdd1078-fig-0001-m.jpg)
Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone - Perlstein - 2022 - Clinical Pharmacology in Drug Development - Wiley Online Library
Teva Pharmaceuticals on LinkedIn: #patientsafetyfirst #safeuseofmedicines #improvingpatientslives #tevapharm
Teva Pharmaceuticals hiring Customer Service Analyst II - 2482 in Debrecen, Hajdú-Bihar, Hungary | LinkedIn
![PDF) Unmasking Integration Challenges: The Case of Biogal's Acquisition by Teva Pharmaceutical Industries PDF) Unmasking Integration Challenges: The Case of Biogal's Acquisition by Teva Pharmaceutical Industries](https://i1.rgstatic.net/publication/247886751_Unmasking_Integration_Challenges_The_Case_of_Biogal's_Acquisition_by_Teva_Pharmaceutical_Industries/links/004635360cf84b5ddd000000/largepreview.png)
PDF) Unmasking Integration Challenges: The Case of Biogal's Acquisition by Teva Pharmaceutical Industries
![Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial - The Lancet Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/2c5962f0-7ed4-4eb8-8114-559265448c37/gr1.gif)
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial - The Lancet
![Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study - The Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study - The](https://www.thelancet.com/cms/asset/b1fddfbb-70c1-4bdb-9a3d-e446a8ce8c0e/gr1.gif)
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study - The
![Ops success story teva pharmaceutical hungary final by Konica Minolta Business Solutions Spain, S.A. - Issuu Ops success story teva pharmaceutical hungary final by Konica Minolta Business Solutions Spain, S.A. - Issuu](https://image.isu.pub/140411191012-1a3d46a7ab8c43f08dce2ff4a28cf88e/jpg/page_1.jpg)